BitFuFu Announces Sponsorship of Blockchain Life 2025 in Dubai

(NASDAQ:FUFU), SINGAPORE, Oct. 24, 2025 (GLOBE NEWSWIRE) — BitFuFu Inc. (“BitFuFu” or the “Company”) (NASDAQ: FUFU), a world-leading Bitcoin miner and mining services innovator, is proud to announce its sponsorship of Blockchain Life 2025, taking place October 28-29, 2025, in Dubai, UAE. Blockchain Life is the world's leading forum dedicated to cryptocurrencies, Web3, and blockchain […]

23andMe Research Institute Names Brad Margus and Stephen Quake, D.Phil., to Board of Directors

PALO ALTO, Calif., Oct. 24, 2025 (GLOBE NEWSWIRE) — 23andMe Research Institute, a nonprofit medical research organization, today announced two new members of its Board of Directors. Brad Margus and Stephen Quake, D.Phil., join the Board to provide strategic guidance focused on ensuring operations have the greatest possible impact for generations to come. “With the

Arcutis to Present New Quality of Life and Long-Term Data with ZORYVE(R) (roflumilast) Cream 0.15% and 0.05% for the Treatment of Atopic Dermatitis at the Fall Clinical Dermatology Conference

(NASDAQ:ARQT), New data from Phase 3 studies show once-daily ZORYVE cream helped reduce sleep disruptions in individuals with atopic dermatitis aged greater-than or equal to2 years New long-term data demonstrate that ZORYVE cream was well-tolerated and provided continued disease control for individuals who switched to twice-weekly treatment WESTLAKE VILLAGE, Calif. and LAS VEGAS, Oct. 24,

ITW Reports Third Quarter 2025 Results

(NYSE:ITW), Revenue of $4.1 billion, an increase of 2% with organic growth of 1% Record operating margin of 27.4%, an expansion of 90 bps as enterprise initiatives contributed 140 bps GAAP EPS of $2.81, an increase of 6% excluding prior year divestiture gain Operating cash flow of $1 billion; free cash flow of $0.9 billion,

ChemDiv Extends Discovery and Early Development Partnership with Mondego Bio on Best-in-Class PTPN2 Immuno-Oncology Program

ChemDiv today announced the extension of its discovery and early development partnership with Mondego Bio to advance the company's best-in-class immuno-oncology program targeting PTPN2. The announcement follows Mondego Bio's successful Series A financing led by Biovance Capital with participation from OrbiMed Advisors and Torrey Pines Investment, underscoring strong momentum behind Mondego's strategy.ChemDiv previously supported the

A Ukrainian’s Story About Joe Biden: An Interview with Viktor Shokin

LAGUNA HILLS, Calif., Oct. 24, 2025 (GLOBE NEWSWIRE) — Viktor Shokin, former Ukrainian Prosecutor breaks his silence in an exclusive interview with James Bradley available on UncensoredBeat.com. Shokin returns to the public eye with his new book “Biden's Corruption and War.” The book is his autobiographical account of Joe Biden's immense influence in Ukraine, which

Payman Khales Assumes Role as Integer President and CEO

(NYSE:ITGR), ~ Planned Leadership Transition Completed ~ PLANO, Texas, Oct. 24, 2025 (GLOBE NEWSWIRE) — Integer Holdings Corporation (NYSE: ITGR), a leading global medical device contract development and manufacturing organization (CDMO), today shared that, as part of a planned transition originally announced in April 2025, Payman Khales has assumed the role of President and Chief

Hanmi Financial Declares Cash Dividend of $0.27 per share

(NASDAQ:HAFC), LOS ANGELES, Oct. 24, 2025 (GLOBE NEWSWIRE) — Hanmi Financial Corporation (NASDAQ: HAFC, or “Hanmi”), the parent company of Hanmi Bank (the “Bank”), today announced that its Board of Directors declared a cash dividend on its common stock for the 2025 fourth quarter of $0.27 per share. The dividend will be paid on November

Gentex Reports Third Quarter 2025 Financial Results

(NASDAQ:GNTX), ZEELAND, Mich., Oct. 24, 2025 (GLOBE NEWSWIRE) — Gentex Corporation (NASDAQ: GNTX), a leading supplier of digital vision, connected car, dimmable glass, fire protection technologies, medical devices, and consumer electronics, today reported financial results for the three and nine months ended September 30, 2025. Third Quarter 2025 Highlights Gentex and VOXX International Corporation (“VOXX”)

DOW INVESTOR DEADLINE TUESDAY: Dow Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – RGRD

(NYSE:DOW), SAN DIEGO, Oct. 24, 2025 (GLOBE NEWSWIRE) — Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Dow Inc. (NYSE: DOW) securities between January 30, 2025 and July 23, 2025, all dates inclusive (the “Class Period”), have until this Tuesday, October 28, 2025 to seek appointment as lead plaintiff of the

Scroll to Top